LENSAR, Inc.
LNSRNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $51.7M | $46.0M | $35.7M | $29.4M | $29.5M | $22.8M |
| Operating income | −$24.6M | −$10.7M | −$12.2M | −$20.2M | −$19.7M | −$18.5M |
| Net income | −$34.3M | −$31.4M | −$14.4M | −$19.9M | −$19.6M | −$19.8M |
| Total assets | $71.4M | $66.3M | $69.6M | $55.8M | $66.5M | $79.1M |
| Total liabilities | $83.7M | $47.7M | $22.4M | $13.9M | $11.6M | $11.9M |
| Equity | −$26.0M | $4.9M | $33.4M | $42.0M | $54.9M | $67.2M |
| EPS (diluted) | $-2.87 | $-2.73 | $-1.31 | $-1.96 | $-2.09 | — |
| Shares out. | 11.8M | 11.4M | 11.1M | 11.0M | 10.9M | 10.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −47.6%
- Net margin
- −66.4%
- Return on equity
- 131.7%
- Return on assets
- −48.0%
- Return on capital (ROCE)
- −79.7%
- Liabilities / assets
- 117.1%
- Debt / equity
- —
- Book value / share
- $-2.21
- Revenue growth (YoY)
- 12.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -10.17distress
- Accruals / assets
- −27.2%clean
- Beneish M-Score
- -4.02normal
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Brandes Investment Partners, LpPassive (13G)May 14, 2026
- Blackrock, Inc.Passive (13G)Oct 17, 2025
- Park West Asset Management LlcPassive (13G)May 15, 2025
- Curtis Nicholas TPassive (13G)May 13, 2025
- Dimensional Fund Advisors LpPassive (13G)Apr 15, 2025
- North Run Capital, LpActivist (13D)Mar 25, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 949,471 | 14.3 | -2.7% |
| Apr 30, 2026 | 975,906 | 12.2 | -3.7% |
| Apr 15, 2026 | 1.0M | 11.2 | -0.3% |
| Mar 31, 2026 | 1.0M | 3.2 | +42.2% |
| Mar 13, 2026 | 714,594 | 13.3 | -0.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Item 5.08 · Other material eventMay 29, 2026
- Results of operationsMay 8, 2026
- Director / officer changeApr 15, 2026
- Results of operationsMar 31, 2026
- Entered a material agreement · Terminated a material agreement · Regulation FD disclosureMar 17, 2026
- Other material eventMar 12, 2026
- Regulation FD disclosureFeb 25, 2026
- Shareholder voteDec 19, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.